Sterlin v. Biomune Systems

154 F.3d 1191, 1998 U.S. App. LEXIS 21436, 1998 WL 559333
CourtCourt of Appeals for the Tenth Circuit
DecidedSeptember 2, 1998
Docket97-4074
StatusPublished
Cited by124 cases

This text of 154 F.3d 1191 (Sterlin v. Biomune Systems) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sterlin v. Biomune Systems, 154 F.3d 1191, 1998 U.S. App. LEXIS 21436, 1998 WL 559333 (10th Cir. 1998).

Opinion

MURPHY, Circuit Judge.

Appellant Roman Sterlin (“Plaintiff’) brought this securities fraud class action suit against Biomune Systems, Inc. (“Biomune”), David Derrick, Aaron Gold, Charles J. Quantz, Jack Solomon, Genesis Investment Corporation (“Genesis”), and the Institute for Social and Scientific Development (“Institute”) (collectively, “Defendants”). The district court dismissed the action, concluding that Plaintiffs claims were barred by the statute of limitations. From this dismissal, Plaintiff appeals. This court reverses and remands.

I. BACKGROUND

Biomune is a biotech company which, during the relevant time period, was developing a protein called Immuno-C to be used in enhancing human immune systems. David Derrick was Biomune’s President, CEO, Chairman of the Board, and main spokesperson. Aaron Gold and Charles Quantz were directors of Biomune. Jack Solomon founded Biomune, the Institute, and Genesis, and was a member of Biomune’s Business Advisory Board. Genesis manages Genesis Trust, whose beneficiaries are Solomon’s family members. Genesis Trust was at one time Biomune’s largest shareholder. Both Derrick and Gold were directors of Genesis. The Institute, a Utah corporation, was also a shareholder of Biomune. Gold served as a director of the Institute.

Plaintiff asserts this “action arises from a fraud of massive proportions,” generally consisting of a “scheme to obtain Biomune’s listing on NASDAQ, manipulate Biomune’s finances and inflate the price of Biomune stock in order to dump thousands of Biomune shares on the market and earn million[s] of dollars in profits.” Plaintiffs specific allegations in the Amended Complaint fall into two general categories: those concerning Biom-une’s NASDAQ listing and those concerning Biomune’s alleged misrepresentations regarding the efficacy of Immuno-C. 1

*1193 NASDAQ Listing. Plaintiff alleges that Biomune faced two obstacles in its attempt to obtain a NASDAQ listing. First, Biomune had to convince the Securities and Exchange Commission (“SEC”) that Solomon, who was subject to a consent decree for previous securities violations, did not maintain control over the company. Second, Biomune had to sufficiently increase its capital and surplus so that it could qualify for listing.

On March 7, 1994, NASDAQ notified Biomune that it was deferring consideration of its application pending a review by the NASDAQ Listing Qualifications Committee. NASDAQ was concerned with disciplinary actions taken against “a principal shareholder,” which Plaintiff alleges was Solomon. According to Plaintiff, Derrick drafted numerous affidavits, executed by himself and Gold, falsely attesting that Solomon did not maintain a control relationship with Biomune.

With respect to the manipulation of Biom-une’s capital and surplus, Plaintiff alleges that a “fraud network,” consisting of relatives and friends of Solomon and Derrick, effectuated a “cleanup” of Biomune’s balance sheet. Plaintiff alleges this plan took place in three parts during mid to late 1993. The first part involved an illegal Regulation S 2 offering of securities to increase Biomune’s capital and surplus. The second part of the plan consisted of Biomune’s purchase of Fur-tek Technologies from Brian Furtek, a longtime friend of Derrick, at an inflated price in an attempt to increase Biomune’s asset base. The third and final part was intended to eliminate Biomune’s long-term debt by entering into a phony settlement agreement with Genesis Trust. Plaintiff alleges that all of these transactions were entered into for the purpose of manipulating Biomune’s finances so that Biomune could obtain a NASDAQ listing. Plaintiff further alleges that during 1993 and 1994, Defendants made false and misleading statements regarding the financial stability and commercial success of Biomune.

Immuno-C Misrepresentations. Plaintiff alleges that in late 1993, Biomune retained Dr. Stephen Upton from the University of Kansas to perform Immuno-C testing on mice (the’ “Upton Study”). Plaintiff further alleges that Dr. Upton’s work was preliminary and contained a number of biases. Although several tests were unsuccessful, in one preliminary test Dr. Upton found that Immuno-C seemed to reduce the parasite level in mice, indicating that Immuno-C may be effective in the treatment of intestinal disorders. Plaintiff alleges that beginning with a press release on March 21, ‘ 1994, Defendants “launched their series of false and misleading announcements about the efficacy of Immuno-C based upon Dr. Upton’s results.” 3

Plaintiff further alleges that in late June or early July 1994, Defendants retained Dr. Mark Healey to perform additional testing of Immuno-C on mice. Dr. Healey completed his testing, which included both in vitro and in vivo tests, in early September 1994. The in vivo tests indicated that Immuno-C “did not demonstrate therapeutic efficacy,” though Dr. Healey suggested that further in vivo tests be performed. Dr. Healey’s in vitro tests, however, confirmed that Immu-no-C may be effective, though once again he recommended that further, testing be done.

Despite Dr. Healey’s recommendations, Defendants decided not to proceed with additional in vivo testing nor did they immediately disclose the results of the in vivo studies. Instead, Plaintiff alleges, Defendants disseminated several press releases emphasizing and exaggerating the importance of Dr. Upton’s preliminary study results and Dr. Hea-ley’s in vitro test results. Plaintiff further alleges that as a consequence of Defendants’ *1194 misleading statements, Biomune’s stock consistently traded at over $12.00 per share (pre-split).

On January 18, 1995, Biomune filed its Form 10-KSB for the fiscal year ending September 30, 1994. In the Form 10-K, Biomune disclosed the results of the Healey in vivo study. Plaintiff alleges that as a result of this disclosure, Biomune’s stock fell to $7.50 per share (pre-split) and has never recovered.

On October 12, 1995, Plaintiff brought this class action Complaint 4 on behalf of two classes: all persons who purchased Biomune common stock during the period September 15, 1993 through January 12, 1995 (“fraud class”); and all persons who purchased Biomune common stock contemporaneously with the sales of Biomune stock by Defendants Derrick, Genesis, and the Institute (“insider trading class”). In Count I, against all defendants, Plaintiff alleges a violation of § 10(b) of the Securities Exchange Act of 1934 (“1934 Act”) and Rule 10b-5 promulgated thereunder. In Count II, against Derrick, Gold, Quantz, and Solomon, Plaintiff alleges that each individual defendant is a control person of Biomune and is therefore liable under § 20(a) of the 1934 Act for the allegedly fraudulent conduct of Biomune. Count III, against Derrick, Genesis, and the Institute, alleges a violation of § 10(b) and Rule 10b-5 based on the defendants’ conduct in their positions as officers, advisors, and/or major stockholders. Finally, Count IV, also against Derrick, Genesis, and the Institute, alleges a violation of § 20A of the 1934 Act based on the defendants’ alleged insider trading.

After Plaintiff filed his Complaint, Defendants moved to dismiss, arguing,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bynum v. Municipality, City & County of Denver
550 F. App'x 560 (Tenth Circuit, 2013)
In Re Crocs, Inc. Securities Litigation
774 F. Supp. 2d 1122 (D. Colorado, 2011)
Merck & Co. v. Reynolds
559 U.S. 633 (Supreme Court, 2010)
Lane v. Page
649 F. Supp. 2d 1256 (D. New Mexico, 2009)
Edward J. Goodman Life Income Trust v. Jabil Circuit, Inc.
595 F. Supp. 2d 1253 (M.D. Florida, 2009)
In Re: Merck & Co
Third Circuit, 2008
In Re American Funds Securities Litigation
556 F. Supp. 2d 1100 (C.D. California, 2008)
Markus v. Fried (In Re Geneva Steel LLC)
389 B.R. 231 (D. Utah, 2008)
In Re Zyprexa Products Liability Litigation
549 F. Supp. 2d 496 (E.D. New York, 2008)
Jones v. Henry
260 F. App'x 130 (Tenth Circuit, 2008)
Betz v. Trainer Wortham & Co., Inc.
504 F.3d 1017 (Ninth Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
154 F.3d 1191, 1998 U.S. App. LEXIS 21436, 1998 WL 559333, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sterlin-v-biomune-systems-ca10-1998.